Epstein–Barr Virus‐Related Post‐Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy

Post‐transplant lymphoproliferative disorder (PTLD) is a spectrum of major, life‐threatening lymphoproliferative diseases occurring in the post‐transplant setting. The majority of PTLD is of B‐cell origin and is associated with several risk factors, the most significant being Epstein‐Barr virus (EBV) infection. EBV's in vitro transforming abilities, distinctive latency, clonality within the malignant cells and response to targeted therapies implicate a critical role in the biology of PTLD. This minireview focuses on EBV‐related PTLD pathogenesis, in particular the interplay between aspects of the EBV life cycle and latency with nonviral factors resulting in the wide spectrum of histology and clinical presentations encountered in PTLD. With the increased prevalence of transplantation a rise in the incidence of PTLD may be expected. Therefore the importance of laboratory and animal models in the understanding of PTLD and the development of novel therapeutic approaches is discussed.

• Publication year

  2011

• Venue

  American Journal of Transplantation

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-6143.2011.03499.xPMID 21521464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epstein-Barr virus infection

  2012cited by this paper
• Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients.

  2011cited by this paper
• Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?

  2010cited by this paper
• Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.

  2010influential reference
• High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood.

  2010influential reference
• Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

  2010cited by this paper
• Posttransplant lymphoproliferative disorder following kidney transplant.

  2010cited by this paper
• Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines

  2010cited by this paper
• Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma

  2010cited by this paper
• Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus-positive lymphomas: are we there yet?

  2009cited by this paper
• Priming of protective T cell responses against virus-induced tumors in mice with human immune system components

  2009cited by this paper
• Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation.

  2009cited by this paper
• Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.

  2009cited by this paper
• Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression

  2009cited by this paper
• Treatment of lymphoma with adoptively transferred T cells

  2009cited by this paper
• Activation of the JAK/STAT Pathway in Epstein Barr Virus+‐Associated Posttransplant Lymphoproliferative Disease: Role of Interferon‐γ

  2009cited by this paper
• Standardisation of nucleic acid amplification assays used in clinical diagnostics: a report of the first meeting of the SoGAT Clinical Diagnostics Working Group.

  2009cited by this paper
• Immunodeficiency-associated lymphomas.

  2008cited by this paper
• Molecular and Immunologic Mechanisms of Cancer Pathogenesis in Solid Organ Transplant Recipients

  2008cited by this paper
• EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial

  2008cited by this paper
• A new prognosticator for post‐transplant lymphoproliferative disorders after renal transplantation

  2008cited by this paper
• Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

  2007cited by this paper
• Epstein–Barr virus T‐cell immunity despite rituximab

  2007cited by this paper
• Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab

  2007cited by this paper
• Multicenter Comparison of Different Real-Time PCR Assays for Quantitative Detection of Epstein-Barr Virus

  2007cited by this paper
• A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

  2007cited by this paper
• Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

  2007cited by this paper
• Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients

  2007cited by this paper
• Lymphoproliferative Disorders Related to Immunodeficiencies

  2007cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative Disorders

  2007cited by this paper
• How Useful is PET/CT Imaging in the Management of Post‐Transplant Lymphoproliferative Disease After Liver Transplantation?

  2006cited by this paper
• Engineered T cell receptors and their potential in molecular medicine.

  2006cited by this paper
• EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis1

  2006cited by this paper
• Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients

  2005cited by this paper
• Technology Insight: applications of emerging immunotherapeutic strategies for Epstein–Barr virus-associated malignancies

  2005cited by this paper
• Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status

  2005cited by this paper
• Epstein–Barr virus: 40 years on

  2004influential reference
• Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

  2004cited by this paper
• Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders

  2004cited by this paper
• Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders

  2004cited by this paper
• Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas

  2004cited by this paper
• Expansion in scid mice of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease biopsy material.

  2002cited by this paper
• Post‐Transplant Lymphoproliferative Disorder in the United States: Young Caucasian Males are at Highest Risk

  2002cited by this paper
• Posttransplant lymphoproliferative disorder associated with an epstein-barr-related virus in cynomolgus monkeys1

  2002cited by this paper
• The expression and function of Epstein-Barr virus encoded latent genes

  2000cited by this paper
• Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

  2000cited by this paper
• Epstein-Barr virus infection.

  2000cited by this paper
• Analysis of the T‐cell micro‐environment in Epstein–Barr virus‐related post‐transplantation B lymphoproliferative disease

  1998cited by this paper
• An animal model for acute and persistent Epstein-Barr virus infection.

  1997cited by this paper
• THE FREQUENCY OF EPSTEIN‐BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN

  1988cited by this paper
• Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

  1985cited by this paper

• Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.

  2026cites this paper
• Spinal Epstein-Barr Virus-Related Smooth Muscle Tumors: Narrative Review and Case Study

  2025cites this paper
• Immune Deficiency/Dysregulation-Associated EBV-Positive Classic Hodgkin Lymphoma

  2025cites this paper
• Primary cutaneous EBV+ extranodal NK/T‐cell lymphoma of gamma/delta T‐cell lineage in the posttransplantation setting

  2024cites this paper
• Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China

  2024cites this paper
• Role of Radiology in Assessment of Postoperative Complications of Heart Transplantation.

  2024cites this paper
• Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts

  2024cites this paper
• Epidemiology of Epstein-Barr Virus Chronic High Viral Load in Kidney Transplant Recipients

  2024influential citation
• Epidemiology and Management of Infections in Liver Transplant Recipients

  2024cites this paper
• Mechanistic Understanding of EBV+Lymphoproliferative Disease Development After Transplantation

  2024cites this paper
• Epstein‐Barr virus and host cell 3D genome organization

  2023cites this paper
• Diagnostic Challenge in Renal Transplantation: Splenosis vs. Post-Transplant Lymphoproliferative Disorder—A Case Report

  2023cites this paper
• Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder

  2023cites this paper
• Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis

  2023cites this paper
• Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder

  2023cites this paper
• Epstein–Barr virus‐associated lymphomas decoded

  2023cites this paper
• Herpes Virus Infection in Lung Transplantation: Diagnosis, Treatment and Prevention Strategies

  2023cites this paper
• Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma

  2023cites this paper
• Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation

  2022cites this paper
• Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder

  2022cites this paper
• High PTX3 expression is associated with a poor prognosis in diffuse large B‐cell lymphoma

  2021cites this paper
• Host Genetic Mutations and Expression Analyses in PTLD

  2021cites this paper
• Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

  2021cites this paper
• Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease

  2021cites this paper
• Biological Difference Between Epstein–Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact

  2020cites this paper
• Epstein Barr virus associated smooth muscle tumors in the central nervous system: a case report and systematic review of the literature

  2020cites this paper
• The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

  2019cites this paper
• Infectious disease risks in pediatric renal transplantation

  2019cites this paper
• Management of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Occurring in the Setting of Solid Organ Transplantation: Report of 2 Cases.

  2019cites this paper
• EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.

  2019cites this paper
• Post Transplant Lymphoproliferative Disorder

  2019cites this paper
• Complications Arising from Preparatory Conditioning Regimens for Stem Cell Transplantation

  2019cites this paper
• Remission of Epstein‐Barr virus‐positive post‐transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient

  2019cites this paper
• Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

  2019cites this paper
• CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors

  2018cites this paper
• Epstein–Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas

  2018cites this paper
• Systematic review and meta‐analysis of post‐transplant lymphoproliferative disorder in lung transplant recipients

  2018cites this paper
• Impact of the posttransplant lymphoproliferative disorder subtype on survival

  2018cites this paper
• Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient

  2018cites this paper
• Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation

  2018cites this paper
• The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience

  2018cites this paper
• First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

  2017cites this paper
• Late Complications Following Heart Transplant

  2017cites this paper
• Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.

  2017cites this paper
• Impact of post‐transplant lymphoproliferative disorder subtype on survival

  2017cites this paper
• Posttransplant lymphoproliferative disease and survival in adult heart transplant recipients.

  2017cites this paper
• Viral Infections After Intestinal Transplantation

  2017cites this paper
• Posttransplant Lymphoproliferative Disorders in Neuronal Xenotransplanted Macaques

  2017cites this paper
• Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes

  2017cites this paper
• Inmunosupresores y principales complicaciones en el trasplante renal pediátrico

  2017cites this paper
• EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations

  2016cites this paper
• Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes

  2016cites this paper
• Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation

  2016cites this paper
• Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma?

  2016cites this paper
• Epstein–Barr Virus Infection and Lymphoproliferative Disorders After Transplantation

  2016cites this paper
• Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation

  2016cites this paper
• A Solid Mass in the Chest Wall

  2016cites this paper
• Selective dysregulation of Epstein-Barr virus infection in hypomorphic ZAP70 mutation

  2016cites this paper
• Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.

  2016cites this paper
• Post-transplant Lymphoproliferative Disorder in Transplanted Kidney Causing Urinary Tract Obstruction

  2016cites this paper
• Outcomes of kidney retransplantation in recipients with prior post‐transplant lymphoproliferative disorder

  2016cites this paper
• Time course of immune recovery and viral reactivation following hematopoietic stem cell transplantation

  2016cites this paper
• Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.

  2015cites this paper
• Epstein–Barr virus-positive T/NK-cell lymphoproliferative disorders

  2015cites this paper
• Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation

  2015cites this paper
• Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center

  2015cites this paper
• HLA class I associations with EBV+ post-transplant lymphoproliferative disorder.

  2015cites this paper
• Epstein-Barr Virus–Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management

  2015cites this paper
• Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

  2015cites this paper
• Post-transplant lymphoproliferative disorders.

  2015cites this paper
• Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.

  2015cites this paper
• Complications of immunosuppressive agents therapy in transplant patients.

  2015cites this paper
• Immunodeficiency-associated viral oncogenesis.

  2015cites this paper
• Cancer in the Kidney Transplant Recipient

  2015cites this paper
• Epstein-Barr viral load before a liver transplant in children with chronic liver disease.

  2014cites this paper
• Co-infections, inflammation and oncogenesis: future directions for EBV research.

  2014cites this paper
• Epstein-Barr virus-associated smooth muscle tumors in AIDS patients: a largest case (series).

  2014cites this paper
• EBNA3C Augments Pim-1 Mediated Phosphorylation and Degradation of p21 to Promote B-Cell Proliferation

  2014cites this paper
• Histopathological Syndromes of Intestinal Allograft Rejection and Recurrent Disease

  2014cites this paper
• Adapted Treatment of Epstein–Barr Virus Infection to Prevent Posttransplant Lymphoproliferative Disorder After Heart Transplantation

  2014influential citation
• Human Viruses and Cancer

  2014cites this paper
• Total Synthesis and Assignment of the Absolute Stereochemistry of Xanthoangelol J: Development of a Highly Efficient Method for Claisen—Schmidt Condensation.

  2014cites this paper
• Maintenance Immunosuppressive Therapy

  2014cites this paper
• Controlled Epstein–Barr virus reactivation after allogeneic transplantation is associated with improved survival

  2014cites this paper
• Chapter 35 – Cancer in Dialysis and Kidney Transplant Patients

  2014cites this paper
• Histopathological Syndromes of Liver Allograft Rejection and Recurrent Disease

  2014cites this paper
• Malignancies After Transplantation and Posttransplant Lymphoproliferative Disorder

  2014cites this paper
• A Comprehensive Analysis of the Cellular and EBV‐Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV‐Associated Tumors

  2014cites this paper
• An Epstein-Barr virus-positive diffuse large B-cell lymphoma presenting as multi-organ failure: a catastrophic lymphomatosis with fulminant visceral organ dissemination resulting in a precipitous death in a 59-year-old female with no identifiable etiology for immunodeficiency.

  2014cites this paper
• Multiple Infections and Cancer: Implications in Epidemiology

  2014cites this paper
• Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms

  2013cites this paper
• The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.

  2013cites this paper
• DNA Viral Infections Complicating Lung Transplantation

  2013cites this paper
• Diarrhea in solid-organ transplant recipients: a review of the evidence

  2013cites this paper
• Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.

  2013cites this paper
• Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

  2013cites this paper
• Isolated cerebral post-transplant lymphoproliferative disorder in a lymphoma recipient.

  2013cites this paper
• Complications of Post-Transplant Immunosuppression

  2013cites this paper
• Secondary malignancies: prevalence, screening, prevention, and management guidelines

  2013cites this paper
• Molecular Pathogenesis of B-Cell Posttransplant Lymphoproliferative Disorder: What Do We Know So Far?

  2013cites this paper